Alexander Azoy - 21 Aug 2026 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Reporting relationship: Chief Accounting Officer
Issuer ticker: RCUS
Reported as of: 21 Aug 2026
Net transaction value: -$84,810
SEC form: 4
Accepted by SEC: 24 Aug 2026, 17:52:18 UTC
Prior SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Carolyn Tang, Attorney-in-Fact

Filing notes and source

Key filing fact

Alexander Azoy filed Form 4 for Arcus Biosciences, Inc. (RCUS) on 24 Aug 2026.

Key facts

This page summarizes Alexander Azoy's Form 4 filing for Arcus Biosciences, Inc. (RCUS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Aug 2026, 17:52.

Change

Previous filing in this sequence was filed on 01 Jun 2026.
Current net transaction value: -$84,810.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001771961 Primary reporting owner

Azoy Alexander

Relationship: Chief Accounting Officer
Address: C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD
Signature: /s/ Carolyn Tang, Attorney-in-Fact
Signature date: 24 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCUS transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,827
Change %: +7.1%
Price: $15.44^*
Shares after: 42,408
Date: 21 Aug 2026
Ownership: Direct
Footnotes: F1, F2

RCUS transaction

Common Stock

Sale

Transaction value: -$84,810
Shares: -2,827
Change %: -6.7%
Price: $30.00
Shares after: 39,581
Date: 21 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCUS transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -2,827
Change %: -48%
Price: $0.000000^*
Shares after: 3,073
Date: 21 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,827
Exercise price: $15.44
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Footnote F2

Includes the unvested portion of the Reporting Person's RSU grants.

Footnote F3

The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.